Conditions: Dyskinesia Parkinson's Disease
Keywords: levodopa dyskinesia parkinson's disease AVP-923 dextromethorphan quinidine
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 14
Healthy volunteers: no

Brief summary:
To evaluate the efficacy, safety, and tolerability of AVP-923 capsules containing 45 mg dextromethorphan and 10 mg quinidine (AVP-923-45) compared to placebo for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).

Detailed description:
Proof-of-concept phase 2a, double-blind, randomized, placebo-controlled, crossover study.

Arms:
arm 1: AVP-923-45 twice daily for 14 days arm 2: Placebo twice a day for 14 days

Interventions: intervention 1: AVP-923-45 intervention 2: Placebo
Intervention descriptions: intervention 1: One capsule twice daily for 14 days intervention 2: One capsule twice daily for 14 days

Protocol document: